StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for LFMD yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $4.38 | $4.33 | -1.14% | 0.8M |
| 05-18 | $4.37 | $4.24 | -2.97% | 0.8M |
| 05-19 | $4.22 | $4.30 | +1.90% | 0.7M |
| 05-20 | $4.32 | $4.26 | -1.39% | 0.8M |
| 05-21 | $4.24 | $4.07 | -4.01% | 0.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $50.16M | $194.06M | $186.98M | $126.80M |
Operating Income | $-8.93M | $-7.67M | $-1.45M | $522.78K |
Net Income | $-8.87M | $14.35M | $-5.61M | $-1.80M |
EPS (Diluted) | $-0.20 | $0.25 | $-0.18 | $-0.08 |
Total Assets | $70.12M | $70.41M | $65.98M | $73.56M |
Total Liabilities | $55.09M | $47.25M | $62.62M | $73.18M |
Cash & Equivalents | $34.48M | $36.79M | $23.79M | $36.23M |
Free Cash Flow OCF − CapEx | $339.45K | $6.41M | $9.85M | $10.79M |
Shares Outstanding | 47.53M | 46.66M | 46.58M | 45.04M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.